Unlock Your Wealthier Future Today
We've been selecting winning stocks for 10 years. Get your investing life on the fast track now with our completely free, high-performing stock.
3 Top Competitors to Hims & Hers Health Inc.
The healthcare industry is currently ripe for disruption, so let's look at newly public Hims & Hers' competitors in this lucrative space.
June 18, 2021

Hims & Hers Health Inc. (NYSE: HIMS) went public through a $1.6 billion SPAC deal completed in January 2021. Current CEO Andrew Dudum founded the company in 2017. It provides telehealth services and sells over the counter, prescription drugs, and personal care products online. Hims & Hers' mission is to eliminate stigmas while providing easier access and care for conditions that affect people's daily lives. 

Hims & Hers has impressive financials with $52.3 million in Q1, with revenue growing 75% year-over-year (YoY) and gross margins of 77%. It has also previously stated that it has approximately 91% recurring revenue, which is a good sign for investors due to its predictability. Its customers also like Hims & Hers, with a net promoter score of 65. Many of its competitors in the direct-to-consumer space are private organizations and highly fragmented. We delve into three of its public competitors that operate in the telehealth space. 

Teladoc Health 

Teladoc Health (NYSE: TDOC) is an American telehealth and virtual healthcare company and is the largest player in the space with 52 million members. It estimates that the telehealth space will grow at a 38% compound annual growth rate over the next five years, leaving a massive opportunity for growth. However, the stock has struggled since its merger with Livongo and is down roughly 22% year-to-date.

In Q1 2021, Teladoc reported revenue growth of 151% YoY to $454 million with a gross margin of 67.8% and 3.2 million visits. However, it is unprofitable, reporting a net loss of $199.6 million, growing significantly primarily due to an increase in stock-based compensation. It also raised guidance and is forecasting revenue from $1.97 billion to $2.02 billion. Teladoc is also loved by its customers, with a net promoter score of 95.

Teladoc has also found that 76% of consumers are now interested in virtual care compared to 11% pre-COVID-19. CEO Jason Gorevic believes that telehealth is not just a short-term phenomenon and is an acceleration of an existing trend. Gorevic stated that COVID-19 has accelerated the telehealth market "by four or five years". 

The acquisition of Livongo also creates an added dimension with the management of chronic conditions, which 40% of U.S. adults live with. An increasing number of visits are from non-infectious diseases and demonstrates that telehealth is here to stay. In addition, Teladoc now offers a full suite of products with greater than 15% of chronic care members enrolled in more than one product and demonstrates the synergies of the acquisition. 

Amwell 

Amwell (NYSE: AMWL), formerly known as American Well, is a telemedicine company founded backed by Alphabet and went public in 2020. Amwell is one of the smaller competitors in the space with a market cap of $3.3 billion and provides telemedicine solutions. 

Amwell was founded by brothers Ido and Roy Schoenberg, who serve as the chairman and president, respectively, and co-CEO. The brothers own a considerable stake in the business, which is a positive sign for investors.

In Q1 2021, total visits on the platform were 1.6 million representing 120% growth. Revenue grew to $57.6 million, an increase of 6.5% YoY with a gross margin of 38%, and subscription revenues made up 43% of this. Despite this, its net loss also increased from $25.2 million, compared to $39.8 million. 

Amwell provides telehealth solutions to over 2,000 hospitals and health systems and 81,000 providers, including partnerships with brands such as Philips and tech giant Apple for a heart study. Amwell has also developed a platform called Converge, which is designed to incorporate the clients' comprehensive solutions in one place and is also designed to host third-party apps. Converge will increase its total addressable market through expanded partnerships and optionality, according to management.   

Amazon

Amazon is well-known for its e-commerce offerings but has made strides into the healthcare space in recent years. However, it hasn't all been plain sailing and ended its joint venture in healthcare Berkshire Hathaway and J.P Morgan Chase & Co.

In 2018, Amazon entered the space with its acquisition of PillPack, a full-service pharmacy that delivers to your door. Amazon has also expanded its app-based services of Amazon Care across the U.S in the Summer of 2021. This provides both virtual and in-person care and facilitates remote video chat with physicians, which were previously only available for its workers in Washington. Both Amazon Care and PillPack complement each other. 

Amazon has the financial strength to enter the industry, along with its logistics network, computing, and other resources, which should enable it to compete.

For more great investments such as this, click here to get free access with MyWallSt and access our market-beating shortlist of stocks. It's the best investment you'll ever make.


MyWallSt operates a full disclosure policy. MyWallSt staff currently holds long positions in companies mentioned above. Read our full disclosure policy here.



The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.


Services

Content

Social

Company

Support

Resources


This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.